|
|
 |
| |
Back to MAAUA Scientific Program
Salvage Cryoablation: Results from the COLD Registry
John P Foley1, Aaron E Katz*2, John C Rewcastle*3, Bryan J Donnelly*3, Franco M Lugnani*4, Louis L Pisters*5, J Stephen Jones*6
1Eastern Short Urology Associates, Easton, MD;2Columbia University, New York, NY;3University of Calgary, Calgary, AB, Canada4Society for Cryosurgery, Trieste, Italy5MD Anderson Cancer Center, Houston, TX;6Cleveland Clinic, Cleveland, OH
Introduction: Herein we report contemporary outcomes of salvage cryoablation at several institutions, both academic and community, which have participated in the Cryo On-Line Data (COLD) Registry.
Methods: Data was collected in a secure on-line database for patients undergoing salvage cryoablation. Patients were stratified according to their pre cryoablation (post radiation therapy) PSA score. Kaplan-Meier (KM) analysis was performed with biochemical failure defined according to the 2006 ASTRO definition of biochemical failure of nadir+2.
Results: Twelve physicians participated and 277 patients were entered. The average age was 70.0±7.1 years. Pre treatment PSA was 7.6±8.2 ng/ml and the median Gleason sum was 7. Of the 277 patients 215 (77.6%) had a PSA < 10 ng/ml. Patients were followed for 21.6±24.9 months with 47 having at least five year follow-up. KM analysis demonstrated five-year actuarial biochemical disease free rates of 61.6±6.3% and 26.6±9.8% for patients with a pre cryoablation PSA < 10.0 and ≥ 10 ng/ml, respectfully (p<0.01). The rectal fistula rate was 1.2%, and incontinence was 6.4% with 3.8% requiring pad use 12 months after therapy.
Conclusions: Salvage cryoablation offers a potentially curative option following failed radiation therapy and is associated with an acceptable morbidity profile. Biochemical survival is significantly higher for patients with a pre cryoablation PSA < 10 ng/ml.
Back to MAAUA Scientific Program
|
|
| |
|
|
| |
|
|
|
|
